Eric Bjerkholt

Eric Bjerkholt, listed as finance chief, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Mirum Pharmaceuticals, Inc., Cerus Corp and Chinook Therapeutics, Inc. Over a trading history stretching from 1 January 2016 to 14 September 2026, the count stands at 48 filings.

The open-market side counts 10 purchases for €413k alongside 13 sales for €2.0M. The totals do not cover 5 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 8 share grants and 15 option exercises. In 2026 alone, the filings show no purchases and 11 sales.

In size, the median ticket on the buying side is €12k. Of 10 purchases, 6 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 15 September 2026, the filings show an option exercise in Mirum Pharmaceuticals, Inc. The last insider purchase was made public on 27 March 2024, 935 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.